Nkarta Announces Positive Integrated Safety Results for NKX019 in Ntrust Clinical Trial

Nkarta reported integrated safety results for NKX019 from 40 patients in its Ntrust clinical trial program, presented at ACR Convergence 2026. The company said there were no cases of CRS, ICANS, IEC-HS or GvHD, and no treatment-related deaths or adverse-event-related discontinuations. CEO Paul J. Hastings said the findings support Nkarta’s view of CAR NK cells as a differentiated approach to autoimmune cell therapy; the article gave no financial results or stock-price impact.